Rifabutin-vonoprazan conjugate 1 is an orally active acid-responsive bifunctional molecule. It exhibits activity against Helicobacter pylori with a minimum inhibitory concentration (MIC) of ≤ 0.125 μg/mL and possesses acid suppression effects with an inhibition rate of over 85% at a dose of 2 mg/kg. Additionally, it has anti-ulcer properties. This compound may be utilized in research related to Helicobacter pylori infections and gastric ulcers.